Syndax Pharmaceuticals Inc
SNDX
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.62B
Close$
$-0.85
104.6% downside
Current Fair Value
104.6% downsideOvervalued by 104.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.62 Billion |
|---|---|
| Enterprise Value | $1.49 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.29 |
| Beta | 0.39 |
| Outstanding Shares | 86,621,003 |
Return
| Return on Equity | -584.42% |
|---|---|
| Return on Assets | -51.46% |
| Return on Invested Capital | -44.23% |
Valuation & Multiples
| P/E Ratio | -6.5 |
|---|---|
| PEG | 13.07 |
| Price to Sales | 9.13 |
| Price to Book Ratio | 18.25 |
| Enterprise Value to Revenue | 6.84 |
| Enterprise Value to EBIT | -8.7 |
| Enterprise Value to Net Income | -7 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 11, 2026
EPS Estimate
$-0.58
Average shareholder expectationRevenue Estimate
$73.98 M
Average shareholder expectationNext Earnings Call
Expected Date
August 3, 2026
EPS Estimate
$-0.45
Average shareholder expectationRevenue Estimate
$80.22 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.6640▲ 19.61% |
|---|---|
| Total Calls | 444,400▼ 66.39% |
| Total Puts | 295,100▼ 52.30% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 114.71%▼ 0.62% |
|---|---|
| Total Invested | $2.32B▲ 10.57% |
| Investors Holding | 259▲ 11.00% |
ESG Score
No data
About Syndax Pharmaceuticals Inc
CEO: Arlene Morris